Sarah Bianchi, Evercore ISI public policy chief strategist, joins 'Squawk Box' to discuss the short-term government funding ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $307.2, a high ...

Evercore ISI raised the firm’s price target on BridgeBio (BBIO) to $50 from $45 and keeps an Outperform rating on the shares ...

Retrenchment in industry has led to concerns about the spread of ‘pharmacy deserts’ with limited access to medicines ...

Tax-loss selling candidates such as Nike, could surprise investors with big gains in 2025, say Evercore strategists.

Cabaletta Bio Inc (CABA) stock saw a decline, ending the day at $2.36 which represents a decrease of $-0.02 or -0.84% from the prior close of $2.38. The stock opened at $2.4 and touched a low of $2.25 ...

Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) on December 20 and set a ...

Keefe Bruyette upgraded Evercore (EVR) to Outperform from Market Perform with a price target of $339, up from $269. The firm says that despite ...

Fintel reports that on December 20, 2024, Keefe, Bruyette & Woods upgraded their outlook for Evercore (NYSE:EVR) from Market ...

Across the recent three months, 5 analysts have shared their insights on Evercore (NYSE:EVR), expressing a variety of opinions spanning from bullish to bearish. The table below offers a condensed ...

ChargePoint (NYSE: CHPT) has disappointed a lot of investors since its public debut. The electric vehicle (EV) charging ...

Tesla shares slowed their roll last week, losing 3.5% after leaping more than 12% in each of the two prior weeks, as the US ...